Phenotypes Associated with This Genotype

Genotype
MGI:5492067

• Allelic Composition: Ctsk^tm1.1Rbar/Ctsk^tm1.1Rbar; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

Increase in cancellous bone mass in Ctsk^tm1.1Rbar/Ctsk^tm1.1Rbar Tg(Mx1-cre)1Cgn/0 and Ctsk^tm1.1Rbar/Ctsk^tm1.1Rbar Tg(Itgam-cre)AJva/0 mice

skeleton

abnormal osteoblast differentiation ( J:194492 )

• CFU-ALP and CFU osteoblasts are increased in pIpC-treated mice compared with controls

• however, the number of CFU fibroblasts is normal

abnormal osteoclast differentiation ( J:194492 )

• in pIpC-treated bone marrow macrophages

abnormal osteoblast physiology ( J:194492 )

• osteoblasts from the long bones of pIpC-treated mice exhibit increased ALP activity and formed more mineralized bone nodules compared with control cells

• however, osteoblast proliferation is normal

increased osteoclast cell number ( J:194492 )

• in pIpC-treated mice

abnormal osteoclast physiology ( J:194492 )

• pIpC-treated mice exhibit reduced resorption pit depths compared with control mice

increased trabecular bone volume ( J:194492 )

• in pIpC-treated mice

increased osteoblast cell number ( J:194492 )

• in pIpC-treated mice

increased bone trabecula number ( J:194492 )

• in pIpC-treated mice

increased trabecular bone connectivity density ( J:194492 )

• in pIpC-treated mice with reduced trabecular separation

increased trabecular bone mass ( J:194492 )

• in pIpC-treated mice

cellular

abnormal osteoblast differentiation ( J:194492 )

• CFU-ALP and CFU osteoblasts are increased in pIpC-treated mice compared with controls

• however, the number of CFU fibroblasts is normal

abnormal osteoclast differentiation ( J:194492 )

• in pIpC-treated bone marrow macrophages

abnormal osteoblast physiology ( J:194492 )

• osteoblasts from the long bones of pIpC-treated mice exhibit increased ALP activity and formed more mineralized bone nodules compared with control cells

• however, osteoblast proliferation is normal

immune system

abnormal osteoclast differentiation ( J:194492 )

• in pIpC-treated bone marrow macrophages

increased osteoclast cell number ( J:194492 )

• in pIpC-treated mice

abnormal osteoclast physiology ( J:194492 )

• pIpC-treated mice exhibit reduced resorption pit depths compared with control mice

hematopoietic system

abnormal osteoclast differentiation ( J:194492 )

• in pIpC-treated bone marrow macrophages

increased osteoclast cell number ( J:194492 )

• in pIpC-treated mice

abnormal osteoclast physiology ( J:194492 )

• pIpC-treated mice exhibit reduced resorption pit depths compared with control mice